Abstract
Background/Aims: To evaluate the efficacy and safety of a triptorelin pamoate (11.25 mg) 3-month formulation in the management of central precocious puberty (CPP) (TP Study) and to retrospectively compare it with a triptorelin acetate (11.25 mg) 3-month formulation (TA Study). Methods: We conducted two phase III, multicentre, single-stage, non-comparative, open-label studies. In the TP Study, patients with CPP received an intramuscular injection of triptorelin pamoate 11.25 mg at baseline and 3 months after baseline. Hormonal changes as well as safety and efficacy endpoints were measured at baseline, 3 months, and 6 months. Results: The baseline characteristics of the 37 patients in the TP Study were similar to those of the TA Study population. A suppressed luteinising hormone (LH) response (LH peak ≤3 IU/l) to the gonadotrophin-releasing hormone test at 3 months (primary endpoint) occurred in 83.8 and 82.8% of the cases in the TP and the TA Study, respectively. At 6 months, a suppressed LH response occurred in 86.5 and 96.8% of the cases in the TP and the TA Study, respectively. Pubertal development was slowed in both studies. Adverse events were mild to moderate and resolved without sequelae in the TP Study. Conclusion: Triptorelin pamoate 11.25 mg administered at 3-month intervals is an effective and well-tolerated treatment in patients with CPP. The efficacy and safety profiles appear similar to those reported in the literature for triptorelin acetate 11.25 mg.
Journal Section:
Editor's choice
References
1.
Carel JC, Leger J: Clinical practice. Precocious puberty. N Engl J Med 2008;358:2366-2377.
[PubMed]
2.
Eugster EA, Palmert MR: Precocious puberty. J Clin Endocrinol Metab DOI: http://dx.doi.org/10.1210/jcem.91.9.9997.
3.
Carel JC, Blumberg J, Seymour C, Adamsbaum C, Lahlou N; Triptorelin 3-Month CPP Study Group: Three-month sustained-release triptorelin (11.25 mg) in the treatment of central precocious puberty. Eur J Endocrinol 2006;154:119-124.
[PubMed]
4.
Comite F, Cutler GB Jr, Rivier J, Vale WW, Loriaux DL, Crowley WF Jr: Short-term treatment of idiopathic precocious puberty with a long-acting analogue of luteinizing hormone-releasing hormone. A preliminary report. N Engl J Med 1981;305:1546-1550.
[PubMed]
5.
Crowley WF Jr, Comite F, Vale W, Rivier J, Loriaux DL, Cutler GB Jr: Therapeutic use of pituitary desensitization with a long-acting LHRH agonist: a potential new treatment for idiopathic precocious puberty. J Clin Endocrinol Metab 1981;52:370-372.
[PubMed]
6.
Bertelloni S, Baroncelli GI: Current pharmacotherapy of central precocious puberty by GnRH analogs: certainties and uncertainties. Expert Opin Pharmacother 2013;14:1627-1639.
[PubMed]
7.
Carel JC, Eugster EA, Rogol A, Ghizzoni L, Palmert MR; ESPE-LWPES GnRH Analogs Consensus Conference Group, Antoniazzi F, Berenbaum S, Bourguignon JP, Chrousos GP, Coste J, Deal S, de Vries L, Foster C, Heger S, Holland J, Jahnukainen K, Juul A, Kaplowitz P, Lahlou N, Lee MM, Lee P, Merke DP, Neely EK, Oostdijk W, Phillip M, Rosenfield RL, Shulman D, Styne D, Tauber M, Wit JM: Consensus statement on the use of gonadotropin-releasing hormone analogs in children. Pediatrics 2009;123:e752-e762.
[PubMed]
8.
Oostdijk W, Hummelink R, Odink RJ, Partsch CJ, Drop SL, Lorenzen F, Sippell WG, van der Velde EA, Schultheiss H: Treatment of children with central precocious puberty by a slow-release gonadotropin-releasing hormone agonist. Eur J Pediatr 1990;149:308-313.
[PubMed]
9.
Partsch CJ, Hummelink R, Peter M, Sippell WG, Oostdijk W, Odink RJ, Drop SL: Comparison of complete and incomplete suppression of pituitary-gonadal activity in girls with central precocious puberty: influence on growth and predicted final height. The German-Dutch Precocious Puberty Study Group. Horm Res 1993;39:111-117.
[PubMed]
10.
Carel JC, Lahlou N, Guazzarotti L, Joubert-Collin M, Roger M, Colle M, Chaussain JL: Treatment of central precocious puberty with depot leuprorelin. French Leuprorelin Trial Group. Eur J Endocrinol 1995;132:699-704.
[PubMed]
11.
Chiocca E, Dati E, Baroncelli GI, Cassio A, Wasniewska M, Galluzzi F, Einaudi S, Cappa M, Russo G, Bertelloni S: Central precocious puberty: treatment with triptorelin 11.25 mg. ScientificWorldJournal 2012;2012:583751.
[PubMed]
12.
Martínez-Aguayo A, Hernández MI, Beas F, Iñiguez G, Avila A, Sovino H, Bravo E, Cassorla F: Treatment of central precocious puberty with triptorelin 11.25 mg depot formulation. J Pediatr Endocrinol Metab 2006;19:963-970.
[PubMed]
13.
Carel JC, Lahlou N, Jaramillo O, Montauban V, Teinturier C, Colle M, Lucas C, Chaussain JL: Treatment of central precocious puberty by subcutaneous injections of leuprorelin 3-month depot (11.25 mg). J Clin Endocrinol Metab 2002;87:4111-4116.
[PubMed]
14.
Glab E, Barg E, Wikiera B, Grabowski M, Noczynska A: Influence of GnRH analog therapy on body mass in central precocious puberty. Pediatr Endocrinol Diabetes Metab 2009;15:7-11.
[PubMed]
15.
Jaruratanasirikul S, Thaiwong M: Outcome of gonadotropin-releasing analog treatment for children with central precocious puberty: 15-year experience in southern Thailand. J Pediatr Endocrinol Metab 2011;24:519-523.
[PubMed]
16.
Magiakou MA, Manousaki D, Papadaki M, Hadjidakis D, Levidou G, Vakaki M, Papaefstathiou A, Lalioti N, Kanaka-Gantenbein C, Piaditis G, Chrousos GP, Dacou-Voutetakis C: The efficacy and safety of gonadotropin-releasing hormone analog treatment in childhood and adolescence: a single center, long-term follow-up study. J Clin Endocrinol Metab 2010;95:109-117.
[PubMed]
17.
Mul D, Bertelloni S, Carel JC, Saggese G, Chaussain JL, Oostdijk W: Effect of gonadotropin-releasing hormone agonist treatment in boys with central precocious puberty: final height results. Horm Res 2002;58:1-7.
[PubMed]
18.
Nabhan ZM, Feezle LK, Kunselman AR, Johnson NB, Lee PA: Normal adult height among girls treated for central precocious puberty with gonadotropin-releasing hormone analog therapy. J Pediatr Endocrinol Metab 2009;22:309-316.
[PubMed]
19.
Carel JC, Roger M, Ispas S, Tondu F, Lahlou N, Blumberg J, Chaussain JL: Final height after long-term treatment with triptorelin slow release for central precocious puberty: importance of statural growth after interruption of treatment. French study group of Decapeptyl in Precocious Puberty. J Clin Endocrinol Metab 1999;84:1973-1978.
[PubMed]
20.
Manasco PK, Pescovitz OH, Feuillan PP, Hench KD, Barnes KM, Jones J, Hill SC, Loriaux DL, Cutler GB Jr: Resumption of puberty after long term luteinizing hormone-releasing hormone agonist treatment of central precocious puberty. J Clin Endocrinol Metab 1988;67:368-372.
[PubMed]
21.
Kauli R, Kornreich L, Laron Z: Pubertal development, growth and final height in girls with sexual precocity after therapy with the GnRH analogue D-TRP-6-LHRH. A report on 15 girls, followed after cessation of gonadotrophin suppressive therapy. Horm Res 1990;33:11-17.
[PubMed]
22.
Mansfield MJ, Beardsworth DE, Loughlin JS, Crawford JD, Bode HH, Rivier J, Vale W, Kushner DC, Crigler JF Jr, Crowley WF Jr: Long-term treatment of central precocious puberty with a long-acting analogue of luteinizing hormone-releasing hormone. Effects on somatic growth and skeletal maturation. N Engl J Med 1983;309:1286-1290.
[PubMed]
23.
Roger M, Chaussain JL, Berlier P, Bost M, Canlorbe P, Colle M, Francois R, Garandeau P, Lahlou N, Morel Y, et al: Long term treatment of male and female precocious puberty by periodic administration of a long-acting preparation of D-Trp6-luteinizing hormone-releasing hormone microcapsules. J Clin Endocrinol Metab 1986;62:670-677.
[PubMed]
24.
Neubig RR: Mind your salts: when the inactive constituent isn't. Mol Pharmacol 2010;78:558-559.
[PubMed]
25.
Saesmaa T, Totterman AM: Dissolution studies on ampicillin embonate and amoxycillin embonate. J Pharm Biomed Anal 1990;8:61-65.
[PubMed]
26.
Berge SM, Bighley LD, Monkhouse DC: Pharmaceutical salts. J Pharm Sci 1977;66:1-19.
[PubMed]
27.
Bowker MJ: A procedure for salt selection and optimization; in Stahl PH, Wermuth CG (eds): Handbook of Pharmaceutical Salts: Properties, Selection, and Use. Weinheim, Wiley-VCH, 2008, pp 161-189.
28.
Decapeptyl SR 11.25 mg: summary of product characteristics. 2016. http://www.medicines.org.uk/emc/medicine/13851/SPC/Decapeptyl +SR+11.25mg/.
29.
Greulich WW, Pyle SI: Radiographic Atlas of Skeletal Development of the Hand and Wrist, ed 2. Stanford, Stanford University Press, 1959.
30.
Tanner JM: Growth at Adolescence, ed 2. Oxford, Blackwell Scientific, 1962.
31.
Keating GM: Triptorelin embonate (6-month formulation). Drugs 2010;70:347-353.
[PubMed]
32.
Lundström EA, Rencken RK, van Wyk JH, Coetzee LJ, Bahlmann JC, Reif S, Strasheim EA, Bigalke MC, Pontin AR, Goedhals L, Steyn DG, Heyns CF, Aldera LA, Mackenzie TM, Purcea D, Grosgurin PY, Porchet HC: Triptorelin 6-month formulation in the management of patients with locally advanced and metastatic prostate cancer: an open-label, non-comparative, multicentre, phase III study. Clin Drug Investig 2009;29:757-765.
[PubMed]
33.
Zhao P, Sharir H, Kapur A, Cowan A, Geller EB, Adler MW, Seltzman HH, Reggio PH, Heynen-Genel S, Sauer M, Chung TD, Bai Y, Chen W, Caron MG, Barak LS, Abood ME: Targeting of the orphan receptor GPR35 by pamoic acid: a potent activator of extracellular signal-regulated kinase and β-arrestin2 with antinociceptive activity. Mol Pharmacol 2010;78:560-568.
[PubMed]
34.
Abashzadeh S, Dinarvand R, Sharifzadeh M, Hassanzadeh G, Amini M, Atyabi F: Formulation and evaluation of an in situ gel forming system for controlled delivery of triptorelin acetate. Eur J Pharm Sci 2011;44:514-521.
[PubMed]
35.
Asmus LR, Kaufmann B, Melander L, Weiss T, Schwach G, Gurny R, Möller M: Single processing step toward injectable sustained- release formulations of triptorelin based on a novel degradable semi-solid polymer. Eur J Pharm Biopharm 2012;81:591-599.
[PubMed]
36.
Asmus LR, Tille JC, Kaufmann B, Melander L, Weiss T, Vessman K, Koechling W, Schwach G, Gurny R, Möller M: In vivo biocompatibility, sustained-release and stability of triptorelin formulations based on a liquid, degradable polymer. J Control Release 2013;165:199-206.
[PubMed]
37.
National Center for Biotechnology Information. PubChem Compound Database. https://pubchem.ncbi.nlm.nih.gov/compound/ 25080282.
38.
National Center for Biotechnology Information. PubChem Compound Database. https://pubchem.ncbi.nlm.nih.gov/compound/ 25074469.
© 2016 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2016
You do not currently have access to this content.
